MedTrace Logo

IncobotulinumtoxinA (Xeomin) to Treat Focal Hand Dystonia

NCT03977493 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2026-03-19

No results posted yet for this study

Summary

This study is a multicenter, double-blind, randomized placebo controlled, parallel group, superiority trial in order to test the superiority of intramuscular injections of IncobotulinumtoxinA against placebo using a 1:1 allocation ratio.

Conditions

  • Focal Hand Dystonia

Interventions

DRUG

Xeomin

One injection of 2.5 to 40 U in each muscle. Injection repeated after 6 weeks if considered necessary

DRUG

Placebo - Concentrate

One injection in each muscle.

Sponsors & Collaborators

  • Clinical Trial Unit Ente Ospedaliero Cantonale

    collaborator OTHER

  • Alain Kaelin

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-21
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03977493 on ClinicalTrials.gov